Part D plan preference for higher-cost hepatitis C drugs led to higher Medicare and beneficiary spending
Effective Aug 25, 2022
Published Aug 29, 2022
Last Reviewed Aug 25, 2022
On August 11, the OIG published a review of the utilization of hepatitis C drugs in Medicare Part D compared to utilization of the same drugs in Medicaid in 2019 and 2020. The review was conducted because preliminary research indicated that Part D beneficiaries were using higher-cost hepatitis C drugs rather than the generic versions that were increasingly being used by Medicaid beneficiaries.
You must log in to view the content you requested.
Not a subscriber? Start accessing the article you’re seeking right away plus weekly, physician practice-specific news, analysis, guidance and specific tools that enable your practice to stay compliant and profitable during times of increased regulatory scrutiny.
Need multi-user access? Ensure uninterrupted individual access and maximum coding productivity for your whole team. For site license inquiries call: 1-855-CALL-DH1
Part B News is how you level the playing field and take control of the financial impact that the changing health care landscape has on your practice. When you subscribe to Part B News, you get step-by-step instructions from the nation's leading physician practice management experts on how to not just survive – but thrive – from changes at CMS and private payers. Plus, through this web site and its forums, you plug into a community of peers who'll share exactly what's working and what's not as questions arise in your practice.
A subscription to Part B News is the physician practice manager’s best tool to ensure that your practice collects every dollar it deserves. Our $25,000 guarantee ensures that your subscription will pay for itself at least 50 times over or we will refund the full year’s subscription fee.
To learn more about subscribing to Part B News, visit the DecisionHealth store right now.